The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
For example there are 3 different timescales given for two clinical trials for Glioma and ASD. Previous guidance was IND approval for ASD expected by the end of 2023 with trial assumed some time after than in 2024, no particular timescales for Glioma:
- Both trials starting by the end of this calendar year (bit earlier than previously expected)
- ASD trial within the next 12 months
- IND for ASD trial expected end of 2024 (suggesting the trial probably wouldn't start until early 2025, a year later than expected)
Clearly these are all very different and can't all be correct. I suspect the third one at least is a typo and might have mislead a few into kneejerk reactions this morning. There is also the fact end-Q2 for the full PK/PD results has turned into Q2/Q3. I suspect this indicates an expected minor slippage into early Q3 (otherwise why not just state Q3 given it's 3 weeks away) in which case again it could have been communicated far better.
I hope they put out a clarification RNS or at least a CEO interview where these things can be tidied up as these facts/expectations clearly matter.
The information in today's RNS is imo badly worded and structured, and there are a few contradictions and ambiguities. I've emailed the company for some clarifications.
Still not sure how you gather another 12 month wait for anything positive etc. as that is not what the RNS says.
Https://www.rrrplc.com/wp-content/uploads/2023/06/2023.05.31_RRR_GM_Chairmans_Letter_to_Shareholders_FINAL_WEB.pdf
Bell wants authority to issue a gazillion new shares.
Hmm so there is another company called African Lithium Resources (ALR) whose sole director is Bell and whose controlling interest is owned by RRR, but it is NOT the ALR which RRR owns a controlling stake of and who Bell tweets about, just a complete coincidence.. LOL pull the other one!
Https://find-and-update.company-information.service.gov.uk/company/14231987/officers
Same **** as in charge of RRR.
Good luck Helpful!
Typo "It's NOT just like"
It's just like Stalicla have just woken up one day and decided to gamble on whether SFX-01 can treat autism - there have been at least 5 clinical trials already that showed a significant positive effect of sulforaphane on behaviour and cognitive function in ASD patients. It's already well established that sulforaphane - the active ingredient in SFX-01 has a positive effect on ASD patients - it's hardly the 'snake oil route'!!
"I just can't fathom that.. drugs could relieve autism"
There are already drugs that relieve autism symptoms but they come with significant side effects.
I suggest you have a read of Stalicla's website. Their whole modus operandus is precision medicine which tailors the treatment to the individual. They have broken down patients into subgroups using their 'DEPI' technology and SFX-01 is their candidate for one of those subgroups. Also (CJ39) there's no mention of combining it with other drugs here - you might be thinking of the studies showing positive effects from combining SFX-01 with radiotherapy in breast cancer.
Just watched the recording and I get the opposite impression. Government acknowledges that Shanta is owed the VAT, government made Shanta an offer (which Shanta didn't agree to), still in discussions with the government.
So to me I get the impression that the relationship with the government is very good, to be able to have these discussions.
Mr 300k still there on the bid at 3.52. A few more sells at the c.3.5p level and he might get filled.
Yes people do seem to exaggerate on gold movements, especially downward ones. FWIW there is a clear uptrend from the ~$1600 low in November touching the ~$1800 low in early March. If it continues that trend I expect we'll see a drift down to ~$1950 over the next week or so and then onwards and upwards from there.
Can't see 35-40p at this stage, but 7-10p could well be on the cards.
Https://www.linkedin.com/embed/feed/update/urn:li:activity:7062368039505141760
An update on the Glioblastoma investigator sponsored study/pre-clinical work would be nice.